Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Eptinezumab in Healthy Japanese Subjects
NCT04336449Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Apr 2020
- Primary completion
- Aug 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of eptinezumab in migraine (3 arms), sponsored by Lundbeck. Primary endpoints: Maximum Observed Plasma Concentration at Week 12, Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at Week 12 and 2 more. Started Apr 2020; status: completed.
02
Drugs
eptinezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04336449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04336449.